Display options
Cite
Shin SH, Yahng SA, Yoon JH, et al. Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation. Blood Res. 2013;48(1):55-7doi: 10.5045/br.2013.48.1.55.
Shin, S. H., Yahng, S. A., Yoon, J. H., Lee, S. E., Cho, B. S., & Kim, Y. J. (2013). Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation. Blood research, 48(1), 55-7. https://doi.org/10.5045/br.2013.48.1.55
Shin, Seung-Hwan, et al. "Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation." Blood research vol. 48,1 (2013): 55-7. doi: https://doi.org/10.5045/br.2013.48.1.55
Shin SH, Yahng SA, Yoon JH, Lee SE, Cho BS, Kim YJ. Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation. Blood Res. 2013 Mar;48(1):55-7. doi: 10.5045/br.2013.48.1.55. Epub 2013 Mar 25. PMID: 23589797; PMCID: PMC3625009.
Copy Download .nbib Format: NLM
Share it on

Blood Res. 2013 Mar;48(1):55-7. doi: 10.5045/br.2013.48.1.55. Epub 2013 Mar 25.

Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation.

Blood research

Seung-Hwan Shin, Seung-Ah Yahng, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Yoo-Jin Kim

Affiliations

  1. Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.

PMID: 23589797 PMCID: PMC3625009 DOI: 10.5045/br.2013.48.1.55

Abstract

Tacrolimus is a widely used immunosuppressive agent for the prophylaxis of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation (HSCT). Since tacrolimus is primarily metabolized by the liver, hepatic dysfunction may affect its metabolism. Hepatic veno-occlusive disease (VOD) is an early complication of HSCT that results in hepatic dysfunction, suggesting that VOD may affect tacrolimus metabolism. We report a case of hepatic VOD accompanied by a sustained high blood trough level of tacrolimus despite its discontinuation. The findings of this case suggest that the elimination of tacrolimus can be markedly delayed in patients with hepatic VOD, and that the clinician should carefully modulate the drug dosage for these patients.

Keywords: Hematopoietic stem cell transplantation; Tacrolimus; Veno-occlusive disease

References

  1. Clin Pharmacokinet. 1991 Jul;21(1):42-69 - PubMed
  2. Transplant Proc. 1991 Dec;23(6):3175-8 - PubMed
  3. Mayo Clin Proc. 2003 May;78(5):589-98 - PubMed
  4. Bone Marrow Transplant. 2000 Jul;26(1):109-11 - PubMed
  5. Blood. 1998 Oct 1;92(7):2303-14 - PubMed
  6. Transpl Int. 2005 Oct;18(10):1215-7 - PubMed
  7. Transplant Proc. 1990 Feb;22(1):57-9 - PubMed
  8. Clin Pharmacokinet. 2004;43(10):623-53 - PubMed
  9. Bone Marrow Transplant. 1998 Jan;21(1):23-8 - PubMed
  10. Clin Pharmacol Ther. 1995 Mar;57(3):281-90 - PubMed
  11. Am J Pathol. 1987 Jun;127(3):549-58 - PubMed
  12. Bone Marrow Transplant. 1999 Nov;24(10):1053-6 - PubMed
  13. Drug Metab Pharmacokinet. 2007 Oct;22(5):328-35 - PubMed

Publication Types